Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Cipla has submitted that in response to media queries on vaccine distribution, the company would be releasing the following statement: ‘Cipla has been at the forefront of Covid care. We are in the process of seeking clarity & guidance from the Government of India for exploring the possible roadmap for vaccine importation to India. At this stage, no definitive terms have been finalised and hence, the Company cannot comment further’.
The above information is a part of company’s filings submitted to BSE.
